Company intelligence / Profile preview
iCoat Medical
Stockholm, Swedenicoatmedical.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Positive results reported from Phase 1/2a trial in September 2023. The company completed a Phase 1/2 randomized, placebo-controlled, double-blind trial evaluating safety and tolerability of ex-vivo deceased donor kidney allograft treatment with TUM012 to minimize ischemic reperfusion injury after kidney transplantation[4][5].
- Therapeutic areas
- ImmunologyCardiovascular
- Modalities
- Small molecule drugsChemical drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Collaborations with leading academic institutions
Beyond the preview
Go deeper on iCoat Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iCoat Medical.